This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pfizer (PFE) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 23% and 7.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Down -23.84% in 4 Weeks, Here's Why You Should You Buy the Dip in Brooks (AZTA)
by Zacks Equity Research
Brooks (AZTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Azenta (AZTA) Beats Q1 Earnings Estimates
by Zacks Equity Research
Brooks (AZTA) delivered earnings and revenue surprises of 100% and 1.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Azenta (AZTA) Q3 Earnings Beat Estimates
by Zacks Equity Research
Brooks (AZTA) delivered earnings and revenue surprises of 50% and 0.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (FLGT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 6.85% and 2.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Azenta (AZTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Brooks (AZTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Azenta (AZTA) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Brooks (AZTA) delivered earnings and revenue surprises of 9.09% and 2.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
1Life Healthcare, Inc. (ONEM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
1Life Healthcare, Inc. (ONEM) delivered earnings and revenue surprises of 4.08% and 2.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Azenta (AZTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Brooks (AZTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Brooks (AZTA) Climb 57% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 56.7% in Brooks (AZTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.